Mavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM
Authors:
- Ozlem BilenOBOzlem Bilen
- Arnon AdlerAAArnon Adler
- Rachel BastiaenenRBRachel Bastiaenen
- James P. MacNamaraJMJames P. MacNamara
- Elizabeth ParatzEPElizabeth Paratz
- Elad MaorEMElad Maor
- Michael AradMAMichael Arad
- Matthew GoldMGMatthew Gold
- Nirav PatelNPNirav Patel
- Cliff PruettCPCliff Pruett
- Edward BurfordEBEdward Burford
- Garima AroraGAGarima Arora
Open Access
- 1 February 2026
- journal article
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (1) , e005502
Abstract
BACKGROUND: Mavacamten has been shown to improve cardiac function and symptoms in patients with symptomatic (New York Heart Association class II–III) obstructive hypertrophic cardiomyopathy (HCM). Clinical studies suggest that mavacamten monotherapy is efficacious and has a favorable safety profile, but limited evidence exists regarding monotherapy in real-world studies. This analysis aimed to describe the effectiveness and safety outcomes of mavacamten monotherapy in the real-world COLLIGO-HCM study (Mavacamten ObservationaL Evidence Global Consortium in Hypertrophic Cardiomyopathy). METHODS: Patient-level data recorded between April 2022 and February 2025 at 7 sites across 5 countries were extracted. Adult patients with a diagnosis of HCM from 2018 onwards were eligible for inclusion if they had ≥1 mavacamten prescription after the date of diagnosis. Patients were categorized based on background therapy status during mavacamten treatment: mavacamten monotherapy or mavacamten with background therapy (down-titration or no dose modification). RESULTS: Overall, 278 patients were included and received mavacamten (mavacamten monotherapy, n=88; mavacamten with background therapy, n=190). At month 9, most patients achieved ≥1 New York Heart Association class improvement from baseline (mavacamten monotherapy, 60.0%; mavacamten with background therapy, 61.0%). Improvements in resting and Valsalva left ventricular outflow tract gradients from baseline to month 9 were observed in both subgroups; mean left ventricular ejection fraction through month 9 remained ≥62.0% with mavacamten monotherapy and ≥61.4% with mavacamten with background therapy. Two patients in the mavacamten monotherapy subgroup and 1 patient in the mavacamten with background therapy subgroup permanently discontinued treatment owing to left ventricular ejection fraction <50%. CONCLUSIONS: Mavacamten monotherapy was associated with improvements in cardiac function and symptoms, and positive benefits to the risk profile over a 9-month follow-up period; this was consistent with improvements observed in patients treated with mavacamten with background therapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06372457.Keywords
Funding Information
- Bristol-Myers Squibb (N/A)
This publication has 17 references indexed in Scilit:
- Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic CardiomyopathyNew England Journal of Medicine, 2025
- Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathyEuropean Heart Journal, 2024
- Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: Observations from a tertiary care centerProgress in Cardiovascular Diseases, 2024
- Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyJAMA Cardiology, 2023
- 2023 ESC Guidelines for the management of cardiomyopathiesEuropean Heart Journal, 2023
- Effect of Beta-Blocker Therapy on the Response to Mavacamten in Patients with Symptomatic Obstructive Hypertrophic CardiomyopathyEuropean Journal of Heart Failure, 2023
- Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction TherapyJACC, 2022
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2020
- Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibersProceedings of the National Academy of Sciences, 2018
- Hypertrophic CardiomyopathyJACC, 2014